The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_024675.3(PALB2):c.2559C>T (p.Gly853=)

CA269540

126660 (ClinVar)

Gene: PALB2
Condition: hereditary breast cancer
Inheritance Mode: Autosomal dominant inheritance
UUID: f11ca490-40a5-4cbc-bd48-5e9869d438f1
Approved on: 2023-04-05
Published on: 2023-04-07

HGVS expressions

NM_024675.3:c.2559C>T
NM_024675.3(PALB2):c.2559C>T (p.Gly853=)
NC_000016.10:g.23629231G>A
CM000678.2:g.23629231G>A
NC_000016.9:g.23640552G>A
CM000678.1:g.23640552G>A
NC_000016.8:g.23548053G>A
NG_007406.1:g.17127C>T
ENST00000261584.9:c.2559C>T
ENST00000261584.8:c.2559C>T
ENST00000565038.1:n.131C>T
ENST00000568219.5:c.1674C>T
NM_024675.4:c.2559C>T
NM_024675.4(PALB2):c.2559C>T (p.Gly853=)
More

Likely Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"
Met criteria codes 2
PVS1 PM5_Supporting
Not Met criteria codes 3
PP3 PM2 PS3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PALB2 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hereditary Breast, Ovarian and Pancreatic Cancer VCEP
The c.2559C>T (p.Gly853=) variant is a synonymous (silent) variant in PALB2. This variant has a minor allele frequency in gnomAD of 0.00001758 in the non-Finnish European population (PM2_Supporting, BS1, and BA1 are not met). This alteration is observed to introduce a cryptic splice site causing a 29 base pair deletion in exon 6, resulting in a frameshift leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PMID: 31843900, 32133419). This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (PALB2 p.Tyr1183*) as classified by the HBOP VCEP, and is expected to be more deleterious. In summary, this variant meets criteria to be classified as likely pathogenic for autosomal dominant hereditary breast and pancreatic cancer and autosomal recessive FANCN based on the ACMG/AMP criteria applied as specified by the HBOP VCEP. (PVS1(RNA), PM5_supporting criteria)
Met criteria codes
PVS1
The c.2559C>T (p.Gly853=) variant in PALB2 is observed to introduce a cryptic splice site causing a 29 base pair deletion in exon 6, resulting in a frameshift leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PMID: 31843900, 32133419).
PM5_Supporting
This alteration results in a termination codon upstream of the most C-terminus pathogenic alteration (PALB2 p.Tyr1183*) as classified by the HBOP VCEP, and is expected to be more deleterious (PM5_Supporting).
Not Met criteria codes
PP3
Splice AI and varSEAK predict splice defect; cannot be applied in addition to PVS1
PM2
Present in 2 alleles in NFE population
PS3
See RNA studies discussed as PVS1 evidence
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.